SCHEMBL2085519

SCHEMBL2085519

COc1cccc(CCNC(=O)N(C)c2cccc(-c3ccc(CCC(=O)O)cc3-c3cccc(C(F)(F)F)c3)c2)c1

nearest known ligand 0.51

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 2/20 0.51
MEN1 O00255 1/20 0.51
KMT2A Q03164 1/20 0.51
HSD17B1 P14061 1/20 0.43
HSD17B2 P37059 1/20 0.43
FFAR1 O14842 4/20 0.42
DGAT2 Q96PD7 2/20 0.42
FFAR4 Q5NUL3 3/20 0.42
TDP1 Q9NUW8 1/20 0.42
ROCK2 O75116 2/20 0.40
ROCK1 Q13464 1/20 0.40
OPRM1 P35372 1/20 0.40
OPRD1 P41143 1/20 0.40
OPRK1 P41145 1/20 0.40
CTSL P07711 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4611227 0.83 KCNH2 (0.45) KDM4EMEN1KMT2AFFAR1ROCK2
SCHEMBL2083300 0.83 FFAR1 (0.50) FFAR1FFAR4OPRM1OPRD1OPRK1
SCHEMBL2081691 0.83 PTAFR (0.46) FFAR1
SCHEMBL4970904 0.81 MEN1 (0.46) KDM4EMEN1KMT2AHSD17B2FFAR1
SCHEMBL4610356 0.80 FFAR1 (0.51) FFAR1FFAR4
SCHEMBL2081800 0.77 FFAR1 (0.50) KDM4EMEN1KMT2AFFAR1FFAR4
SCHEMBL2084954 0.76 FFAR4 (0.51) KDM4EFFAR1FFAR4TDP1
SCHEMBL2085155 0.76 FFAR1 (0.49) FFAR1FFAR4
SCHEMBL2084192 0.76 MTNR1A (0.44) ROCK2ROCK1OPRM1OPRD1OPRK1
SCHEMBL2084731 0.76 OPRM1 (0.42) FFAR1ROCK2OPRM1OPRD1OPRK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7863332-B2 Biaromatic compound activators of PPARγ receptors and cosmetic/pharmaceutical compositions comprised thereof GALDERMA RESEARCH & DEVELOPMENT (FR) 2011-01-04 US claimed
EP-1781297-B1 NOVEL BIAROMATIC COMPOUNDS THAT ACTIVATE PPAR TYPE RECEPTORS, AND USE THEREOF IN COSMETIC OR PHARMACEUTICAL COMPOSITIONS GALDERMA RES & DEV (FR) 2008-10-15 EP claimed
US-20070213336-A1 Biaromatic compound activators of ppargamma receptors and cosmetic/pharmaceutical compositions comprised thereof GALDERMA RESEARCH & DEVELOPMENT (FR) 2007-09-13 US claimed
US-7863332-B2 Biaromatic compound activators of PPARγ receptors and cosmetic/pharmaceutical compositions comprised thereof GALDERMA RESEARCH & DEVELOPMENT (FR) 2011-01-04 US disclosed
EP-1781297-B1 NOVEL BIAROMATIC COMPOUNDS THAT ACTIVATE PPAR TYPE RECEPTORS, AND USE THEREOF IN COSMETIC OR PHARMACEUTICAL COMPOSITIONS GALDERMA RES & DEV (FR) 2008-10-15 EP disclosed
US-20070213336-A1 Biaromatic compound activators of ppargamma receptors and cosmetic/pharmaceutical compositions comprised thereof GALDERMA RESEARCH & DEVELOPMENT (FR) 2007-09-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070213336-A1 Biaromatic compound activators of ppargamma receptors and cosmetic/pharmaceutical compositions comprised thereof PPARG, PPARA, PPARD KDM4E 3918/4885MEN1 4745/4885KMT2A 3074/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.